Latest news

• Ocrevus surge keeps Roche smiling in Q3

  However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led

• Roche’s Alecensa backed by China’s National Drug Administration

  Roche’ s Alecensa backed by China’ s National Drug Administration. Approved to treat ALK-positive lung cancer. ... which today received an approval to market its lung cancer treatment Alecensa in the country.

• Daily Brief: DeepMind and NHS success in AI eyecare, Bayer invests in COPD, Alecensa OK in Scotland

  Daily Brief: DeepMind and NHS success in AI eyecare, Bayer invests in COPD, Alecensa OK in Scotland. ... Alecensa is challenging Pfizer’s existing ALK+ lung cancer treatment, Xalkori, alongside another challenger, Novartis’Zycadia.

• Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

  Strong launches for new medicines Ocrevus, Tecentriq and Alecensa, especially in Germany, partially offset the loss in Europe.

• Daily Brief: Health and social care still divided, Opdivo rejected in bladder cancer, Xalkori extends reach

  Xalkori is for now keeping one step ahead of rival treatments, such as Novartis’Zykadia, which gained NICE approval for use in ALK+ patients in January, and Roche’s Alecensa, which